Loading…
Nordic provider of care services for the elderly and people with disabilities, operating group homes and care facilities.
Nordic provider of care services for the elderly and people with disabilities, operating group homes and care facilities.
In one line: A Nordic elderly/disability care operator like a smaller Genesis Healthcare.
Moat: narrow (regulatory licence, scale, installed base). Licensed care-provider status and scale in a publicly funded, contract-based Nordic welfare model.
Headquarters: Stockholm, Sweden · Founded: 2001
Size Ambea (AMBEA.ST) is a Sweden Health Care company (Medical/Nursing Services) with a market value of $1.63B, the 98th largest of 221 Sweden companies the cockpit tracks. Shares closed at SEK 191.80 on 6 Nov 2026.
Performance Over six months the shares gained 30.5%, against +17.9% for the median peer and +8.2% for the Sweden market (cap-weighted) — 7th highest of 21 in its peer set.
Growth Revenue grew 13.3% over the last twelve months (peer median +5.9%); the operating margin is 8.3% (peer median 3.2%).
Valuation It trades at 15.8× forward earnings against a peer median of 40.1× (2nd cheapest of 16).
Price implies For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -6 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 1.0 points above its cost of capital (5.2% WACC).
Next results Next results expected around 11 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | SEK 16.9B | SEK 16.0B | SEK 14.2B | SEK 13.3B | SEK 12.6B |
| Revenue growth | — | +13% | +7% | +5% | — |
| Gross profit | SEK 1.41B | SEK 2.70B | SEK 2.44B | SEK 2.08B | SEK 1.89B |
| EBITDA | SEK 3.01B | SEK 2.71B | SEK 2.48B | SEK 1.95B | SEK 1.61B |
| Net income | SEK 788M | SEK 665M | SEK 620M | SEK 455M | SEK 366M |
| Free cash flow | SEK 2.21B | SEK 2.05B | SEK 1.96B | SEK 1.63B | SEK 1.34B |
| Capital expenditure | SEK 128M | SEK 139M | SEK 117M | SEK 90.0M | SEK 105M |
| Total debt | SEK 13.2B | SEK 12.6B | SEK 10.8B | SEK 10.7B | SEK 11.0B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Ambea AMBEA.ST | $1.63B | +30% | +13% | 8% | 15.8× | 1.7% |
| Attendo ATT.ST | $1.92B | +23% | -1% | 10% | 17.7× | 1.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | AMBEA.ST | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +8.1% | +7.3% | 9th highest of 21 |
| 6-month return | +30.5% | +17.9% | 7th highest of 21 |
| Distance from 52-week high | -1.1% | -17.1% | highest of 21 |
| Revenue growth (TTM) | +13.3% | +5.9% | 8th highest of 21 |
| Operating margin | 8.3% | 3.2% | 7th highest of 21 |
| Forward P/E | 15.8× | 40.1× | 2nd cheapest of 16 |
| Growth the price implies (Req g, 7 yrs) | 1.7% | 17.4% | 2nd least demanding of 15 |
| Growth delivered (Del g) | +7.7% | +9.7% | 6th lowest of 15 |
| Hurdle (Req g minus delivered) | -6.0 pp | +10.4 pp | 3rd least demanding of 15 |
| ROIC minus cost of capital | +1.0 pp | -4.1 pp | 5th highest of 20 |
| EV / EBITDA | 9.7× | 22.6× | 4th cheapest of 14 |
| Net debt / EBITDA | 4.4× | 1.6× | 6th most indebted of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Ambea AMBEA.ST | Sweden | $1.63B | +30% | +13% | 8% | 15.8× | 1.7% | +7.7% |
| Ping An Healthcare and Technology 1833.HK | Hong Kong | $1.63B | -47% | +8% | 3% | 40.1× | 15.0% | -5.1% |
| Vijaya Diagnostic Centre VIJAYA.NS | India | $1.60B | +22% | +24% | 32% | 64.3× | 39.3% | +16.7% |
| Teladoc Health TDOC | United States | $1.60B | +21% | -2% | -5% | n/a | -5.2% | +18.3% |
| Sonida Senior Living SNDA | United States | $1.58B | -14% | +49% | -11% | n/a | n/a | n/a |
| Personalis PSNL | United States | $1.71B | +164% | -13% | -164% | n/a | n/a | n/a |
| Azenta AZTA | United States | $1.72B | +104% | +1% | -3% | 103.7× | 56.0% | +8.9% |
| Dr. Agarwal's Health Care AGARWALEYE.NS | India | $1.74B | +15% | +22% | 15% | 89.1× | 41.9% | +26.9% |
| U.S. Physical Therapy USPH | United States | $1.48B | +68% | +11% | 10% | 30.4× | 19.9% | +13.0% |
| GeneDx WGS | United States | $1.86B | +53% | +25% | -12% | 98.7× | n/a | n/a |
| Clariane CLARI.PA | France | $1.40B | -20% | +1% | 6% | 8.6× | 6.7% | +6.5% |
| agilon health AGL | United States | $1.90B | +109% | 0% | -4% | 67.5× | n/a | n/a |
| Emeis EMEIS.PA | France | $1.94B | -30% | +4% | 3% | n/a | 21.3% | +8.5% |
| Dian Diagnostics 300244.SZ | China | $1.97B | +11% | -5% | 9% | 25.2× | 2.4% | -1.1% |
| H.U.Group 4544.T | Japan | $1.35B | +24% | +1% | 2% | 41.0× | 10.1% | +2.1% |
| Guangzhou Kingmed Diagnostics 603882.SS | China | $1.99B | +5% | -3% | 7% | 31.7× | 6.7% | -6.1% |
| Diagnostyka DIA.WA | Poland | $1.29B | -5% | +19% | 15% | 18.4× | 6.9% | +18.9% |
| OPKO Health OPK | United States | $1.29B | +52% | -11% | -29% | n/a | n/a | n/a |
| Lumexa Imaging LMRI | United States | $1.29B | +29% | +8% | 3% | 18.6× | n/a | n/a |
| Pennant PNTG | United States | $1.27B | +1% | +38% | 6% | 24.0× | 21.1% | +19.4% |
| Metropolis Healthcare METROPOLIS.NS | India | $1.25B | +12% | +20% | 18% | 45.6× | 32.4% | +10.5% |